With the new European Union Deforestation Regulation on the horizon, should the industry adopt a more responsible approach to procurement when sourcing cocoa beans and other ingredients? Sign up for our free webinar to discuss!
The World Cocoa Foundation Partnership Meeting ended as it began, with an address from President Chris Vincent. Two days ago, in his opening remarks, he struck an upbeat chord, pleased with the internal changes in the organisation and a strategy refresh focussing on ‘landscapes,’ that is less Washington-based, and chimed with the meeting’s theme of ‘Aligning for Global Action’
Tofacitinib achieves higher clinical and biochemical remission rates than vedolizumab for patients with anti-TNF-exposed ulcerative colitis, although the effect diminishes over time, say Dutch scientists.
Clinicians often face uncertainty in deciding when and how to position biologics versus Janus kinase (JAK) inhibitors in anti-tumor necrosis factor (TNF) therapy-refractory patients with ulcerative colitis (UC). To shed light on this dilemma, Marjolijn Duijvestein, MD, of Amsterdam University Medical Center in the Netherlands, and colleagues compared the relative effectiveness and safety of vedolizumab (Entyvio) and the JAK inhibitor tofacitinib (Xeljanz) in anti-TNF-exposed UC patients in the Dutch Initiative on Crohn and Colitis (ICC) Registry.
We’ve come quite a long way in getting companies to support a Living Income for farmers. Just seven years ago, the Living Income Community of Practice gathered…